HeartBeat Bio of Austria and Germany’s BiotxAI established a strategic partnership to identify and validate genetic targets for heart failure therapy. Using BiotxAI’s Mendelian randomization platform and HeartBeat Bio’s induced pluripotent stem cell-derived cardiac organoid models, the collaboration aims to discover novel targets and accelerate drug development. HeartBeat Bio holds rights to initiate discovery programs or partnerships from validated targets, with BiotxAI eligible for milestone payments. This collaboration exemplifies integration of AI and human biologics in therapeutic innovation.